Tsuchiya, Masami



Faculty of Pharmacy, Department of Pharmacy Division of Drug Informatics (Shiba-Kyoritsu)


Project Senior Assistant Professor (Non-tenured)/Project Assistant Professor (Non-tenured)/Project Lecturer (Non-tenured)

Career 【 Display / hide

  • 2007.05

    Tohoku University Hospital, University Hospital Pharmaceutical Sciences, Pharmacist

  • 2013.04

    Miyagi Cancer Center, Department of Pharmacy, Pharmacist

  • 2020.04

    Miyagi Cancer Center, Department of Pharmacy, Chief Pharmacist

  • 2020.04

    Tohoku University, 大学院薬学研究科 病態分子薬学分野, 分野研究員

  • 2021.09

    Miyagi Prefectural Hospital Organization Miyagi Cancer Center, がん薬物療法研究部, Researcher

display all >>

Academic Background 【 Display / hide

  • 2003.04

    Tohoku University, Faculty of Pharmaceutical Sciences, 総合薬学科

  • 2015.10

    Tohoku University, Graduate School of Pharmaceutical Sciences, Division of Biochemical Pharmacology and Therapeutics


Books 【 Display / hide

  • がん化学療法レジメン管理マニュアル

    青山, 剛, 池末, 裕明, 内田, まやこ, 佐藤, 淳也, 高田, 慎也, 土屋, 雅美, 濱, 敏弘, 医学書院, 2023.02,  Page: xvii, 908p

  • 臨床腫瘍薬学

    日本臨床腫瘍薬学会, じほう, 2022.09,  Page: x, 961p

  • まず知っておきたい!がん治療のお金,医療サービス事典

    山﨑, 知子, 全日本病院出版会, 2021.06,  Page: 242p

  • がん薬物療法副作用管理マニュアル

    吉村, 知哲, 田村, 和夫, 川上, 和宜, 松尾, 宏一, 林, 稔展, 大橋, 養賢, 小笠原, 信敬, 医学書院, 2021.03,  Page: 14,377p

  • 感染・がん : 薬トレ : 薬剤師の臨床センスを磨くトレーニングブック

    望月, 敬浩, 中村, 安孝, 川上, 和宜, 大橋, 養賢, 原田, 知彦, 南山堂, 2020.08,  Page: xii, 417p

display all >>

Papers 【 Display / hide

  • The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study.

    Hironori Fujii, Masami Tsuchiya, Daichi Watanabe, Ryo Otsuka, Daisuke Hirate, Katsuyuki Takahashi, Makiko Go, Toshihiro Kudo, Kazuhiro Shimomura, Yosuke Ando, Shinya Tani, Takao Takahashi, Katsuhisa Hayashi, Miki Chin, Naomi Matsunami, Masaya Takahashi, Akiko Hasegawa, Takashi Uchida, Hironobu Hashimoto, Akiko Kubo, Nobuhisa Matsuhashi, Akio Suzuki, Junichi Nishimura, Naoki Inui, Hirotoshi Iihara

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 32 ( 5 ) 291 - 291 2024.04

     View Summary

    BACKGROUND: Trifluridine/tipiracil (TAS-102) is an oral anticancer drug with adequate efficacy in unresectable colorectal cancer, but frequently also induces chemotherapy-induced nausea and vomiting (CINV). To investigate the occurrence of CINV and antiemetic therapy in patients with colorectal cancer treated with TAS-102 (JASCC-CINV 2001). METHODS: We conducted a multicenter, prospective, observational study in patients with colorectal cancer who received TAS-102 without dose reduction for the first time. Primary endpoint was the incidence of vomiting during the overall period. Secondary endpoints were the incidence of nausea, significant nausea, anorexia, other adverse events (constipation, diarrhea, insomnia, fatigue, dysgeusia) and patient satisfaction. Patient diaries were used for primary and secondary endpoints. All adverse events were subjectively assessed using PRO-CTCAE ver 1.0. and CTCAE ver 5.0. RESULTS: Data from 100 of the 119 enrolled patients were analyzed. The incidence of vomiting, nausea, and significant nausea was 13%, 67%, and 36%, respectively. The incidence of vomiting in patients with and without prophylactic antiemetic therapy were 20.8% and 10.5%, respectively. Prophylactic antiemetics were given to 24% of patients, of whom 70% received D2 antagonists. Multivariate Cox proportional hazards analysis showed that experience of CINV in previous treatment tended to be associated with vomiting (hazard ratio [HR]: 7.13, 95% confidence interval [CI]: 0.87-58.5, P = 0.07), whereas prophylactic antiemetic administration was not (HR: 1.61, 95 CI: 0.50-5.21, P = 0.43). With regard to patient satisfaction, the proportion of patients who were "very satisfied," "satisfied," "slightly satisfied" or "somewhat satisfied" was 81.8%. CONCLUSIONS: The low incidence of vomiting and high patient satisfaction suggest that TAS-102 does not require the use of uniform prophylactic antiemetic treatments. However, patients with the experience of CINV in previous treatment might require prophylactic antiemetic treatment.

  • Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.

    Kaori Takahashi, Ryuji Uozumi, Toru Mukohara, Tetsu Hayashida, Midori Iwabe, Hirotoshi Iihara, Kanako Kusuhara-Mamishin, Yuko Kitagawa, Masami Tsuchiya, Mika Kitahora, Aiko Nagayama, Shinkichi Kosaka, Yoshimi Asano-Niwa, Tomoko Seki, Koji Ohnuki, Akio Suzuki, Fumiko Ono, Manabu Futamura, Hitoshi Kawazoe, Tomonori Nakamura

    The oncologist  2024.02

    ISSN  1083-7159

     View Summary

    BACKGROUND: Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment. PATIENTS AND METHODS: This multicenter, retrospective, observational study, conducted across 4 medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio. RESULTS: The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival period was 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% CI, 0.70-2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61-2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Adverse event incidence and severity were similar in both groups. CONCLUSION: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.

  • Evaluation of hospital pharmacists’ activities using additional reimbursement for infection prevention as an indicator in small and medium-sized hospitals

    Yuichi Tasaka, Takeshi Uchikura, Shiro Hatakeyama, Daisuke Kikuchi, Masami Tsuchiya, Ryohkan Funakoshi, Taku Obara

    Journal of Pharmaceutical Health Care and Sciences (Springer Science and Business Media LLC)  10 ( 1 )  2024.01

     View Summary



    Hospitals in Japan established the healthcare delivery system from FY 2018 to 2021 by acquiring an additional reimbursement for infection prevention (ARIP) of category 1 or 2. However, research on outcomes of ARIP applications related to the practice of hospital pharmacists is scarce.


    This study assessed the activities performed by hospital pharmacists in hospitals with 100 to 299 beds, using ARIP acquirement as an indicator, using data from an annual questionnaire survey conducted in 2020 by the Japanese Society of Hospital Pharmacists on the status of hospital pharmacy departments. Out of the survey items, this study used those related to hospital functions, number of beds, number of pharmacists, whether the hospital is included in the diagnosis procedure combination (DPC) system, average length of stay, and nature of work being performed in the analysis. The relationship between the number of beds per pharmacist and state of implementation of pharmacist services or the average length of hospital stay was considered uncorrelated when the absolute value of the correlation coefficient was within 0–0.2, whereas the relationship was considered to have a weak, moderate, or strong correlation when the absolute value ranged at 0.2–0.4, 0.4–0.7, or 0.7–1, respectively.


    Responses were received from 3612 (recovery rate: 43.6%) hospitals. Of these, 210 hospitals meeting the criteria for ARIP 1 with 100–299 beds, and 245 hospitals meeting the criteria for ARIP 2 with 100–299 beds, were included in our analysis. There was a significant difference in the number of pharmacists, with a larger number in ARIP 1 hospitals. For the pharmacist services, significant differences were observed, with a more frequency in ARIP 1 hospitals in pharmaceutical management and guidance to pre-hospitalization patients, sterile drug processing of injection drugs and therapeutic drug monitoring. In DPC hospitals with ARIP 1 (173 hospitals) and 2 (105 hospitals), the average number of beds per pharmacist was 21.7 and 24.7, respectively, while the average length of stay was 14.3 and 15.4 d, respectively. Additionally, a weak negative correlation was observed between the number of pharmacist services with “Fairly well” or “Often” and the number of beds per pharmacist for both ARIP 1 (R = -0.207) and ARIP 2 (R = -0.279) DPC hospitals. Furthermore, a weak correlation (R = 0.322) between the average number of beds per pharmacist and the average length of hospital stay was observed for ARIP 2 hospitals.


    Our results suggest that lower beds per pharmacist might lead to improved pharmacist services in 100–299 beds DPC hospitals with ARIP 1 or 2. The promotion of proactive efforts in hospital pharmacist services and fewer beds per pharmacist may relate to shorter hospital stays especially in small and medium-sized hospitals with ARIP 2 when ARIP acquisition was used as an indicator. These findings may help to accelerate the involvement of hospital pharmacists in infection control in the future.

  • Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002)

    Senri Yamamoto, Masami Tsuchiya, Hirotoshi Iihara, Yoh Hayasaki, Kyoko Hori, Yasuo Kumakura, Daichi Watanabe, Hideki Sakai, Satoshi Nakagawa, Akiko Kudoh, Hajime Oishi, Nobuhiro Kado, Makiko Go, Kota Mashima, Takashi Uchida, Moeka Yasue, Akimitsu Maeda, Kimihiro Nishino, Koji Matsumoto, Shinya Sato, Yutaka Ueda, Kensuke Tomio, Katsuhisa Hayashi, Motoki Takenaka, Masahiko Mori, Hiroaki Kajiyama, Yoshimasa Bomoto, Shiro Suzuki, Takuma Ishihara, Akio Suzuki, Masakazu Abe

    Journal of Cancer (Ivyspring International Publisher)  15 ( 6 ) 1487 - 1497 2024.01

    ISSN  1837-9664

  • Survey on Attitudes toward Career Visions for Hospital Pharmacists

    Hitoshi Kawazoe, Masami Tsuchiya, Maki Todo, Azusa Hara, Yumiko Ohnishi, Yoichi Osato, Satoko Hori

    YAKUGAKU ZASSHI (Pharmaceutical Society of Japan)  143 ( 8 ) 683 - 691 2023.08

    Lead author, Accepted,  ISSN  0031-6903

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 患者中心のがんチーム医療の推進のために J-TOPのリーダーシップ教育の取り組み

    土屋 雅美

    日本癌治療学会学術集会抄録集 ((一社)日本癌治療学会)  61回   YP1 - 4 2023.10

  • 病院薬剤師のキャリアパス(後編)

    大橋 裕丈, 大野 能之, 土屋 雅美, 細野 智美, 安 武夫, 鈴木 慶介, 小林 映子, 金 素安, 本多 秀俊

    東京都病院薬剤師会雑誌 ((一社)東京都病院薬剤師会)  72 ( 3 ) 121 - 128 2023.05

    ISSN  1345-7624

  • 自由単語記載形式アンケートによるJASPOスタートアップ・ブラッシュアップセミナー2021セミナー内容に関する解析

    寺薗 英之, 吉川 直樹, 小川 大介, 森 理保, 土屋 雅美, 牧 陽介, 板垣 文雄, 河原 陽介, 西村 佳子, 篠原 佳祐, 岩本 義弘, 益子 寛之, 米村 雅人, 内田 まや子

    日本臨床腫瘍薬学会雑誌 ((一社)日本臨床腫瘍薬学会)  30   423 - 423 2023.05

  • 病院薬剤師のキャリアパス(前編)

    大橋 裕丈, 土屋 雅美, 細野 智美, 安 武夫, 鈴木 慶介, 小林 映子, 金 素安

    東京都病院薬剤師会雑誌 ((一社)東京都病院薬剤師会)  72 ( 2 ) 60 - 68 2023.03

    ISSN  1345-7624

  • 周産期医薬品情報の創出のための基盤構築に関する研究(第一報)

    酒井隆全, 佐藤ユリ, 畠山史朗, 菊池大輔, 土屋雅美, 近藤悠希, 八鍬奈穂, 佐藤泉美, 岡田裕子, 小原拓

    日本医薬品情報学会総会・学術大会講演要旨集 ((一社)日本医薬品情報学会)  25th (Web)   133 - 133 2023

display all >>

Presentations 【 Display / hide

  • 病院薬剤部門の現状調査および診療報酬改定特別調査データの利活用推進に関する調査・研究

    小原 拓, 内倉 健, 菊池 大輔, 田坂 祐一, 土屋 雅美, 畠山 史朗, 舟越 亮寛




  • An analysis of trends in tele-prescription of anticancer agents during the COVID-19 pandemic

    Masami Tsuchiya




  • イトラコナゾール錠へのリルマザホン混入事例 JADERを用いた解析

    土屋 雅美, 小原 拓, 眞野 成康




  • 病院薬剤部門の医薬品副作用自発報告に関する業務実態の解明

    土屋 雅美, 菊池 大輔, 畠山 史朗, 田坂 祐一, 内倉 健, 舟越 亮寛, 小原 拓, 日本病院薬剤師会令和3年度学術第5小委員会




  • 病院薬剤師における医療提供施設間での患者情報共有に関する調査

    菊池 大輔, 土屋 雅美, 畠山 史朗, 田坂 祐一, 内倉 健, 舟越 亮寛, 小原 拓, 日本病院薬剤師会令和3年度学術第5小委員会




display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • Impact of anticancer drug administration to pregnant women on birth and infant outcomes using healthcare and medical big data analysis


    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, No Setting

  • 新型コロナウイルス流行下におけるがん薬物療法の安全性の検討


    日本学術振興会, 科学研究費助成事業 奨励研究, 奨励研究, No Setting

  • 妊娠可能年齢女性のがん罹患とがん治療の実態把握及び妊婦と児のアウトカム評価


    日本学術振興会, 科学研究費助成事業 奨励研究, 奨励研究, No Setting

     View Summary


  • 多発性骨髄腫治療における抗血栓薬の静脈血栓症予防効果の検証と医療経済的評価


    日本学術振興会, 科学研究費助成事業 奨励研究, 奨励研究, No Setting

     View Summary

    【方法】宮城県立がんセンターの電子カルテデータから、2012年1月~2017年12月のサリドマイド、レナリドミド、ポマリドミド使用患者を抽出し、アスピリン、ワルファリンカリウム、低分子ヘパリン、アピキサバン、エドキサバン、リバーロキサバン併用の有無、VTE発症の有無などを調査した。VTEの定義はICD-10コードに基づいて、I26.9 : 急性肺性心の記載のない肺塞栓症、I82.2 : 大静脈の塞栓症及び血栓症、I80.1 : 大腿静脈の静脈炎及び血栓(性)静脈炎、I80.2 : 下肢のその他の深在血管の静脈炎及び血栓(性)静脈炎、I82.8 : その他の明示された静脈の塞栓症及び血栓症、I82.9 : 部位不明の静脈の塞栓症及び血栓症とした。


Courses Previously Taught 【 Display / hide

  • Medical Informatics

    Tohoku University